阿斯利康2025年财报发布，营收增长8%，肿瘤业务表现强劲

Core Insights - AstraZeneca reported total revenue of $58.739 billion for the year 2025, representing an 8% year-over-year increase [1][2] - The oncology segment generated $25.619 billion, a 14% increase, accounting for 44% of total revenue [1][2] - For Q4 2025, revenue was $15.503 billion, meeting market expectations, with core operating profit of $4.1 billion primarily due to increased R&D investment [1][2] - The 2026 guidance anticipates mid-to-high single-digit revenue growth and double-digit core profit growth, with R&D investment remaining around 24% of revenue [1][2] Recent Events - On February 10, 2026, AstraZeneca entered a strategic partnership with China National Pharmaceutical Group, potentially worth $18.5 billion, to acquire a long-acting peptide technology platform for the GLP-1 weight loss drug market [3] - At the 2026 J.P. Morgan Healthcare Conference, the company disclosed 37 late-stage indication expansion projects, including the ADC drug targeting CLDN18.2, with data expected in the first half of 2026, and successful Phase II studies for the oral GLP-1 drug elecoglipron [3] - On February 12, 2026, the former president of the China region, Wang Lei, was prosecuted for illegal drug imports and healthcare fraud, with the company potentially facing a customs fine of up to $12.5 million, though no new developments were reported for 2026 [3] - The company plans to invest over $100 billion in China by 2030 for R&D and production facilities, including an inhalation aerosol base in Qingdao expected to be operational by 2028 [3] Stock Performance - AstraZeneca's stock experienced significant volatility from February 9 to 13, 2026, with a price fluctuation of 6.00% and an amplitude of 10.18%, reaching a high of $206.71 on February 13 and a low of $187.06 on February 9 [4] - As of February 13, the latest closing price was $204.62, reflecting a slight increase of 0.05%, with a year-to-date gain of 16.59% [4] Institutional Perspectives - A report from Mingge Value Analysis on February 11, 2026, indicated that AstraZeneca's 2025 financial results validate its innovation-driven strategy, with strong growth in the oncology business supporting overall performance; the report assigned a "Buy" rating with a target price of $78, suggesting the stock is undervalued compared to industry averages and has a clear long-term growth path [5]